Close
  Indian J Med Microbiol
 

Figure 4: Prostate cancer lung metastases can develop metabolic progression without neuroendocrine differentiation. Computed tomography-guided biopsy (March 2019) of the left hilar mass showed morphology consistent with prostatic adenocarcinoma. The disease was negative for neuroendocrine features (nuclear molding and scant cytoplasm). The tumor was positive for prostate-specific antigen and prostatic acid phosphatase and negative for thyroid transcription factor-1, CK7, napsin A, and CDX2. Micrographs of the bronchial biopsy with selected immunostains are shown. (A) ×4 hematoxylin and eosin (H+E), (B) H+E ×20, (C) prostate-specific antigen, (D) CD56, (E) chromogranin A, and (F) thyroid transcription factor-1. Insets for thyroid transcription factor-1 (F) and chromogranin A (E) positive controls. The CD56 immunostain (D) marked benign bronchial cells; the adenocarcinoma was negative for CD56

Figure 4: Prostate cancer lung metastases can develop metabolic progression without neuroendocrine differentiation. Computed tomography-guided biopsy (March 2019) of the left hilar mass showed morphology consistent with prostatic adenocarcinoma. The disease was negative for neuroendocrine features (nuclear molding and scant cytoplasm). The tumor was positive for prostate-specific antigen and prostatic acid phosphatase and negative for thyroid transcription factor-1, CK7, napsin A, and CDX2. Micrographs of the bronchial biopsy with selected immunostains are shown. (A) ×4 hematoxylin and eosin (H+E), (B) H+E ×20, (C) prostate-specific antigen, (D) CD56, (E) chromogranin A, and (F) thyroid transcription factor-1. Insets for thyroid transcription factor-1 (F) and chromogranin A (E) positive controls. The CD56 immunostain (D) marked benign bronchial cells; the adenocarcinoma was negative for CD56